{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T22:48:35Z","timestamp":1770504515323,"version":"3.49.0"},"reference-count":54,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2010,6,1]]},"DOI":"10.1185\/03007991003779380","type":"journal-article","created":{"date-parts":[[2010,4,30]],"date-time":"2010-04-30T11:14:26Z","timestamp":1272626066000},"page":"1485-1496","source":"Crossref","is-referenced-by-count":36,"title":["Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium\/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study"],"prefix":"10.1185","volume":"26","author":[{"given":"Eduard","family":"Vieta","sequence":"first","affiliation":[{"name":"Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall","family":"Owen","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Wallingford, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Baudelet","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Braine-l\u2019Alleud, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert D.","family":"McQuade","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Marcus","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Wallingford, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2010,4,30]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07450-0"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1080\/15622970410029924"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0710"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0702"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2005.00212.x"},{"issue":"4","key":"CIT0006","first-page":"1","volume":"159","author":"APA","year":"2002","journal-title":"Am J Psychiatry"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.1.62"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.7.1146"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.182.2.141"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2004.00115.x"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e328080ca57"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000144887.66319.2f"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.07101560"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2008.06.001"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08020189"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.184.4.337"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(09)70827-2"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300203"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2008.09.008"},{"key":"CIT0020","doi-asserted-by":"crossref","unstructured":"Jordan S, Koprivica V, Dunn R, et al. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004;483:45-53","DOI":"10.1016\/j.ejphar.2003.10.025"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)01532-7"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0414"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1003"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"CIT0026","unstructured":"Guy W. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology US Department of Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health, 1976:534-7"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-200012000-00003"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2008.01204.x"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1517\/17425250902911455"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923050-00004"},{"key":"CIT0034","doi-asserted-by":"crossref","unstructured":"Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines, 9th edn. London: Informa Healthcare, 2007","DOI":"10.1201\/b21605"},{"issue":"17","key":"CIT0035","first-page":"12","volume":"10","author":"Correll CU","year":"2007","journal-title":"CNS Drugs"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900015959"},{"key":"CIT0037","doi-asserted-by":"crossref","unstructured":"Fleischhacker W, McQuade R, Marcus R, et al. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry 2009:65:510-7","DOI":"10.1016\/j.biopsych.2008.07.033"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0607"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2006.00308.x"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2008.11.020"},{"issue":"1","key":"CIT0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519010-00001","volume":"19","author":"Newcomer JW","year":"2005","journal-title":"CNS Drugs"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00735.x"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0507"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2005.00234.x"},{"key":"CIT0045","doi-asserted-by":"crossref","unstructured":"De Hert M, Dekker JM, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24:412-24","DOI":"10.1016\/j.eurpsy.2009.01.005"},{"key":"CIT0046","unstructured":"Ramaswamy K, Markowitz JS, Engelhart MA. Sedation, quality of life, and functioning in bipolar patients prescribed risperidone, quetiapine, or olanzapine. American Psychiatric Association Annual Meeting, Atlanta, GA, May 21\u201326 2005"},{"key":"CIT0047","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4088\/JCP.0608e18","volume":"69","author":"Kane JM","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1559"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.6.530"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1159\/000228249"},{"key":"CIT0051","doi-asserted-by":"crossref","unstructured":"Bowden CL, Vieta E, Ice KS, et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010;71:130-7","DOI":"10.4088\/JCP.09m05482yel"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08020189"},{"key":"CIT0053","doi-asserted-by":"crossref","unstructured":"Taylor GJ, Wainwright P. Open label extension studies: research or marketing? BMJ 2005 10;331:572-4","DOI":"10.1136\/bmj.331.7516.572"},{"key":"CIT0054","first-page":"520","volume":"19","author":"Goodwin G","year":"2009","journal-title":"ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/03007991003779380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:24:39Z","timestamp":1635294279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/03007991003779380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,30]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6,1]]}},"alternative-id":["10.1185\/03007991003779380"],"URL":"https:\/\/doi.org\/10.1185\/03007991003779380","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,30]]}}}